olutasidenib
Sign in to saveAlso known as Rezlidhia, 5-[[(1S)-1-(6-chloro-2-oxo-1H-quinolin-3-yl)ethyl]amino]-1-methyl-6-oxopyridine-2-carbonitrile
Olutasidenib, sold under the brand name Rezlidhia, is an anticancer medication used to treat relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation. Olutasidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor. It is taken by mouth.
~3 min read
Encyclopedic overview
6 sectionsContents
- Medical uses
- Society and culture
- Names
- References
- Further reading
- External links
{{Infobox drug | image = Olutasidenib.svg | image_class = skin-invert-image | width = | alt = | caption =
| pronounce = | tradename = Rezlidhia | Drugs.com = | MedlinePlus = | DailyMedID = Olutasidenib | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | class = | ATC_prefix = L01 | ATC_suffix = XM03 | ATC_supplemental =
Excerpted from Wikipedia’s “olutasidenib” article, available under the CC BY-SA 4.0 licence.